Abstract: Process and immune chemotherapeutic/pharmaceutical composition for treatment of canine and human Leishmaniasis comprising a vaccine containing the FML antigen (Fucose Mannose-Ligand) and saponin adjuvant, used in association with chemotherapeutic agents, showing healing property, leaving the dogs previously infected, in the condition of sterile cure of visceral and tegumentary leishmaniasis, characterized by absence of parasites and the overall absence of Leishmania DNA, aiming to stave off the spread of the parasite which causes canine visceral leishmaniasis in dog to the insect transmitter, thus to other dogs and humans. The invention also comprises also the use of the aforementioned composition to produce formulations designed to treat canine visceral leishmaniasis and visceral and murine tegumentary leishmaniasis, human and canine, as well as a kit comprising immune chemotherapeutic agents to treat the same diseases.

Abstract: Process and immune chemotherapeutic/pharmaceutical composition for treatment of canine and human Leishmaniasis comprising a vaccine containing the FML antigen (Fucose Mannose-Ligand) and saponin adjuvant, used in association with chemotherapeutic agents, showing healing property, leaving the dogs previously infected, in the condition of sterile cure of visceral and tegumentary leishmaniasis, characterized by absence of parasites and the overall absence of Leishmania DNA, aiming to stave off the spread of the parasite which causes canine visceral leishmaniasis in dog to the insect transmitter, thus to other dogs and humans. The invention also comprises also the use of the aforementioned composition to produce formulations designed to treat canine visceral leishmaniasis and visceral and murine tegumentary leishmaniasis, human and canine, as well as a kit comprising immune chemotherapeutic agents to treat the same diseases.